上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

未开盘 04-16 16:08:12

11.770

-0.010

-0.08%

最高11.820	最低11.640	成交量336.43万
今开11.790	昨收11.780	日振幅1.53%
总市值436.43亿	流通市值108.17亿	总股本37.08亿
成交额3,942万	换手率0.37%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.77,"timestamp":1776326892006,"preClose":11.78,"halted":0,"volume":3364300,"delay":0,"changeRate":-0.0008488964346349565,"floatShares":919072704,"shares":3708000000,"eps":1.7663882657990089,"marketStatus":"未开盘","change":-0.01,"latestTime":"04-16 16:08:12","open":11.79,"high":11.82,"low":11.64,"amount":39422723,"amplitude":0.01528,"askPrice":11.77,"askSize":1800,"bidPrice":11.76,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":1.7663882657990089,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":0,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.78,"dividendRate":0.038173,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"volumeRatio":1.2440193298106268,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.14,"timestamp":1776322800000,"preClose":17.25,"halted":0,"volume":8364200,"delay":0,"premium":"-40.13"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2627415721","title":"花旗：降上海医药(02607)目标价至13.5港元 反映毛利受压 重申“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2627415721","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627415721?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:33","pubTimestamp":1776152029,"startTime":"0","endTime":"0","summary":"该行认为，管理层执行风险、整合进度慢于预期，及处方药网上销售放宽政策出台慢于预期等，均为下行风险。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260414/20260414153119_10699.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260414/20260414153119_10699.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["601607","02607","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627816804","title":"【券商聚焦】高盛维持上海医药(02607)“沽售”评级 微升目标价至10.3元并上调净利润预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2627816804","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627816804?lang=zh_cn&edition=full","pubTime":"2026-04-13 13:32","pubTimestamp":1776058351,"startTime":"0","endTime":"0","summary":"金吾财讯 | 高盛发表研报指，上海医药(02607)第四季收入685亿元，按年增长4.4%，高于该行预期的659亿元，主要由制造业务板块的稳健表现带动；同期净利润为5.78亿元，按年增长16%，低于该行预期的12亿元，主要由于创新药商业化带动销售开支大幅增加，以及期内确认的投资损失及资产减值。该行将其2026至2027年净利润预测分别上调5.8%及1.7%，以反映销售开支增加及上海和黄药业的合并，引入2028年每股盈利预测1.06元；目标价由10.03港元上调至10.3港元，维持“沽售”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902114","title":"上海医药：公司挂牌转让上海施贵宝项目正有序推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902114","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626902114?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:15","pubTimestamp":1775722547,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问公司挂牌转让所持上海施贵宝股份进展如何？公司今年对创新药研发计划投入由增加吗？上海医药（601607.SH）4月9日在投资者互动平台表示，公司挂牌转让上海施贵宝项目正有序推进中，相关交易进展公司会按照监管要求及时履行信息披露义务，请您继续关注公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093699584342.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699584342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1261432733.SGD","IE00B2B36J28.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","BK4585","LU0267386448.USD","601607","BK0012","IE00BJJMRZ35.SGD","LU1074936037.SGD","BK4534","LU2360032135.SGD","LU0096364046.USD","LU1883839398.USD","LU1670711123.USD","BK0184","LU0321505868.SGD","BK4559","LU1032466523.USD","LU2242646821.SGD","BK4532","LU0061475181.USD","LU1670711040.USD","BK0020","BK0187","LU1323610961.USD","BMY","LU1585245621.USD","LU2133065610.SGD","LU0321505439.SGD","BK0028","02607","LU2125154935.USD","BK0188","LU0237698245.USD","BK1197","BK0183","LU1291159041.SGD","BK4588","LU1868836757.USD","LU0225771236.USD","LU0882574055.USD","LU0306807586.USD","LU1868836914.USD","LU1868837300.USD","BK0209","LU0114720955.EUR","LU0985481810.HKD","LU1093756325.SGD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916959","title":"上海医药(601607.SH)：地高辛片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916959","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916959?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:04","pubTimestamp":1775635449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药信谊药厂有限公司的地高辛片收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。地高辛片适用于1、治疗成人轻度至中度心力衰竭。地高辛可增加左心室射血分数并改善心力衰竭症状，表现为提高运动能力和减少心力衰竭相关住院和急诊治疗，而对死亡率无影响。在可能的情况下，地高辛应与利尿剂和血管紧张素转换酶抑制剂联合使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0099","BK1197","BK0209","BK0188","BK0184","BK0187","BK0020","BK0183","601607","BK0196","BK0012","BK0028","02607","BK0097","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625916857","title":"上海医药：下属公司硫酸妥布霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2625916857","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625916857?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:50","pubTimestamp":1775634600,"startTime":"0","endTime":"0","summary":"4月8日，上海医药（601607/02607）发布公告，近日，公司下属上药禾丰的硫酸妥布霉素注射液收到国家药监局颁发的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品的规格为2ml：80mg，适用于多种感染症状。2025年1月，上药禾丰向国家药监局提出了该药品的一致性评价补充申请，并获得受理，相关研发费用约为438万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698020185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","BK0209","BK1197","BK0175","601607","BK0099","BK0184","BK0187","BK0183","BK0028","BK0012","02607","BK0188","BK0196","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625991306","title":"里昂：升上海医药(02607)目标价至15.2港元 评级“跑赢大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2625991306","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625991306?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:28","pubTimestamp":1775633337,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，上海医药(02607) 2025财年收入2,836亿元人民币，同比增加3%，净利润57.3亿元人民币，同比增加25.7%，均与市场预期基本一致。中药一直是公司生产业务的核心驱动力，公司将继续优先发展创新药物研发以推动增长。该行将其目标价由14.2港元上调至15.2港元，维持“跑赢大市”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625061631","title":"每周股票复盘：上海医药（601607）2025年归母净利润增25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625061631","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625061631?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:52","pubTimestamp":1775325130,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，上海医药报收于17.31元，较上周的16.69元上涨3.71%。本周，上海医药4月2日盘中最高价报17.37元。3月30日盘中最低价报16.54元。上海医药当前最新总市值641.92亿元，在医药商业板块市值排名1/32，在两市A股市值排名286/5193。2025年第四季度，公司单季度主营收入685.07亿元，同比上升4.4%；单季度归母净利润5.77亿元，同比上升15.88%；单季度扣非净利润2.82亿元，同比下降25.65%。负债率61.49%，投资收益31.7亿元，财务费用14.07亿元，毛利率10.73%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173042457","title":"上海医药3月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173042457","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173042457?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:35","pubTimestamp":1775122559,"startTime":"0","endTime":"0","summary":"上海医药于2026年4月2日披露截至2026年3月31日的股份变动月报。报告期内，普通股包括H股与A股的已发行数量均无变化，整体股本结构保持稳定。报告显示，截至3月31日，H股股数为919,072,704股，A股股数为2,789,289,105股，注册股本总额为3,708,361,809元人民币。本月内，无任何新增发行、购回或注销股份活动。截至本月底，该期权数量未发生行使、转让或失效，未导致已发行股份数目变化。月报由联席公司秘书钟涛签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9589a36a1b64e7c7d7a94166c3b09e9b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624466592","title":"上海医药发布2025年业绩报告，营收2835.52亿元，同比增长3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624466592","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624466592?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:35","pubTimestamp":1775039711,"startTime":"0","endTime":"0","summary":"财报显示，公司实现营业收入2835.52亿元，同比增长3.03%；归母净利润57.25亿元，同比增长25.74%。扣非归母净利润为29.80亿元，同比下降26.68%；若进一步剔除非经常性损益影响，扣非后归母净利润为47.21亿元，同比下降5.56%。销售费用达132.06亿元，同比增长3.87%。经营活动现金流净额为61.54亿元，同比增长5.61%。分红方面，公司2025年度拟派发现金红利12.98亿元，叠加半年度已派发的4.45亿元，累计派现17.43亿元，占归母净利润的30.45%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775036336712856794","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624532596","title":"瑞银：升上海医药(02607)目标价至15.2港元 评级为“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2624532596","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624532596?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:38","pubTimestamp":1775032694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，上海医药(02607)去年总收入同比升3%至2,840亿元人民币，纯利同比升25.7%至57.2亿元，经常性纯利同比跌26.7%至29.8亿元人民币，大致上符合预期。将上海医药2026至2028年盈利预测下调1%至上调3%，目标价由15港元上调至15.2港元，评级“买入”。该行指出，考虑到上海医药的定位策略、多元化业务以及在快速增长业务中的竞争优势，该行预计上海医药在“十五五”期间的增长将超越其医药分销同行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623634353","title":"上海医药(02607)发布2025年度业绩，归母净利润57.25亿元，同比上升25.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623634353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623634353?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:12","pubTimestamp":1774876356,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布2025年度业绩，营业收入2835.80亿元，同比增长3.03%。其中：医药工业实现销售收入245.22亿元，同比增长3.33%;医药商业实现销售收入2590.58亿元，同比增长3.00%。归属于上市公司股东的净利润57.25亿元，同比上升25.74%。归属于上市公司股东的净利润同比上升，主要是由于对和黄药业会计核算由合营企业权益法核算变更为子公司核算所产生的一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为47.21亿元，同比下降5.56%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192789190","title":"上海医药(02607)2025年经营摘要：营收稳健增长，聚焦创新与数字化升级","url":"https://stock-news.laohu8.com/highlight/detail?id=1192789190","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192789190?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:58","pubTimestamp":1774875520,"startTime":"0","endTime":"0","summary":"在2025年报告期内，上海医药实现营业收入人民币2,835.80亿元，同比增长3.03%；其中归属于上市公司股东的净利润为人民币57.25亿元，同比上升25.74%，年度利润总额达人民币69.74亿元，整体财务指标持续向好。公司在研发领域投入同比增长9.54%，为未来业务升级奠定了基础。医药工业方面：实现销售收入人民币245.22亿元，同比增长3.33%。报告期内，器械大健康服务实现显著增长，签约项目超过30个，进出口平台也获得进一步巩固。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143776910","title":"上海医药将于派息日待公布派发末期股息每股0.35元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143776910","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143776910?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:53","pubTimestamp":1774875205,"startTime":"0","endTime":"0","summary":"上海医药(02607)\n根据公告，上海医药集团股份有限公司拟派发截至2025年12月31日止年度的末期股息，每10股派发人民币3.5元。董事会已宣布股东批准日期、除净日、记录日及股息派发日均有待公布，派息金额及公司预设派发货币也将另行通知。\n公告显示，按照相关法规要求，公司将根据不同股东类型及其住所地，按10%或20%的税率代扣代缴股息所得税。对于内地个人投资者通过港股通投资本公司H股取得的股息，将按20%税率代扣代缴个人所得税。有关更多详情，请参阅公司2025年度业绩公告及后续发布的股东大会投票结果与派息登记日公告。\n以上安排尚待股东批准及进一步通知，公司后续将另行发布具体时间和细节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623540338","title":"每周股票复盘：上海医药（601607）二羟丙茶碱注射液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2623540338","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623540338?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:10","pubTimestamp":1774725024,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，上海医药报收于16.69元，较上周的16.89元下跌1.18%。本周，上海医药3月23日盘中最高价报16.79元。来自公司公告汇总：上海医药将于2026年4月8日召开2025年年度业绩说明会。公司公告汇总上海医药集团股份有限公司下属上海禾丰制药有限公司的二羟丙茶碱注射液获得国家药品监督管理局批准生产，药品注册证书编号为2026S00781，注册分类为化学药品3类。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0196","BK0184","BK0187","02607","BK0183","BK1197","BK0012","BK0020","601607","BK0097","BK0188","BK0099","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808918","title":"上海医药孙公司被指卷入巨额经济纠纷","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808918","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622808918?lang=zh_cn&edition=full","pubTime":"2026-03-28 04:07","pubTimestamp":1774642068,"startTime":"0","endTime":"0","summary":"总经理下落不明、涉嫌伪造印章、20多家公司牵连……近日，全国第二大医药商业企业上海医药（601607.SH，02607.HK）控股孙公司及其总经理被指卷入巨额经济纠纷。“我的核心诉求是：第一，希望能把240万元中药材款项追回来；第二，上海医药作为国企上市公司，需要对此事公开并妥善处理，需要有人负监管职责；第三，希望此事引起上级纪委监委和国资委的重视。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603283687556246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0209","BK0196","BK0184","BK0187","02607","BK0183","BK1197","BK0012","BK0020","601607","BK0097","BK0188","BK0099","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622834191","title":"上海医药：二羟丙茶碱注射液获批生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2622834191","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622834191?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:40","pubTimestamp":1774510800,"startTime":"0","endTime":"0","summary":"人民财讯3月26日电，上海医药(601607)3月26日公告，近日，公司下属上海禾丰制药有限公司的二羟丙茶碱注射液收到国家药监局颁发的《药品注册证书》，该药品获得批准生产。二羟丙茶碱注射液适用于支气管哮喘、喘息型支气管炎、阻塞性肺气肿等缓解喘息症状。也可用于因心源性肺水肿而致的喘息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685478559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0020","BK0183","BK0012","601607","BK0188","BK0209","BK0097","BK0187","BK0175","BK0099","BK0184","BK1197","02607","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621619870","title":"上海医药：公司控股股东已发布增持计划（请见临时公告2025-083）","url":"https://stock-news.laohu8.com/highlight/detail?id=2621619870","media":"证券日报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621619870?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:29","pubTimestamp":1774351740,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，上海医药在互动平台回答投资者提问时表示，公司始终将市值管理作为长期战略的重要组成部分，多措并举加强市场沟通，注重股东回报。一方面，公司将深耕主业发展，以经营业绩的稳健增长来夯实价值根基，提升内在价值，另一方面，公司也积极寻求多元化、可适用的市值管理工具，传递信心、共享成果。截至目前，公司控股股东已发布增持计划（请见临时公告2025-083）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682748841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK0097","BK0187","BK0196","BK0184","BK1197","BK0099","BK0028","601607","BK0175","BK0183","BK0012","BK0188","BK0209","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621111799","title":"每周股票复盘：上海医药（601607）注射用头孢唑林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621111799","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621111799?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:02","pubTimestamp":1774119738,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，上海医药报收于16.89元，较上周的17.29元下跌2.31%。本周，上海医药3月17日盘中最高价报17.39元。上海医药当前最新总市值626.34亿元，在医药商业板块市值排名1/32，在两市A股市值排名304/5190。该药品适用于治疗敏感细菌所致的多种感染。截至公告日，公司针对该药品的一致性评价已投入研发费用约332.41万元。2025年中国大陆医院采购该药品金额为110,758万元。通过一致性评价有利于提升市场竞争力，扩大市场份额，但存在销售不达预期的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0184","BK0099","BK0012","601607","BK0028","BK0020","BK0187","BK0196","02607","BK0097","BK0188","BK1197","BK0209","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620441803","title":"上海医药(601607.SH)：注射用头孢唑林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2620441803","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620441803?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:37","pubTimestamp":1773733056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)公告，公司下属上海上药新亚药业有限公司(简称“上药新亚”)的注射用头孢唑林钠收到国家药品监督管理局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。注射用头孢唑林钠适用于治疗敏感细菌所致的呼吸道感染、尿路感染、皮肤和软组织感染、骨和关节感染、败血症、感染性心内膜炎、肝胆系统感染、生殖系统感染和围手术期预防感染。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0028","BK0020","BK0012","BK0188","BK0196","601607","BK1197","BK0097","BK0175","BK0187","BK0184","BK0183","BK0099","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619150962","title":"每日卖空追踪 | 上海医药 03月12日卖空量成交1.94万股，卖空比例为1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619150962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619150962?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304233,"startTime":"0","endTime":"0","summary":"上海医药北京时间03月12日，股价较前一交易日持平，卖空量成交1.94万股，较上一交易日减少65.54%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163441a6ba51e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163441a6ba51e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":-0.0159},{"period":"1month","weight":0.0155},{"period":"3month","weight":-0.0076},{"period":"6month","weight":0.007},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.0343}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0203},{"period":"3month","weight":-0.0168},{"period":"6month","weight":0.0454},{"period":"1year","weight":0.2535},{"period":"ytd","weight":0.0298}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005835},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014987},{"month":3,"riseRate":0.533333,"avgChangeRate":0.009535},{"month":4,"riseRate":0.533333,"avgChangeRate":0.0007},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00149},{"month":6,"riseRate":0.466667,"avgChangeRate":-0.011244},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.017077},{"month":8,"riseRate":0.4,"avgChangeRate":0.011563},{"month":9,"riseRate":0.333333,"avgChangeRate":0.013086},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.021401},{"month":11,"riseRate":0.466667,"avgChangeRate":0.029705},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.012575}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}